1 unchanged sentence
Adoption, Modification and Termination of Rule 10b5-1 Plans and Certain Other Trading Arrangements.
−Removed: On August 17, 2023 , Maxine Gowen , a member of our Board of Directors , adopted a Rule 10b5-1 trading plan intended to satisfy the affirmative defense conditions of Rule10b5-1(c)(1) under the Exchange Act.
−Removed: Sales may commence under the plan on November 16, 2023 and the plan terminates on December 31, 2024 , subject to earlier termination in accordance with its terms.
−Removed: The aggregate number of securities to be sold under the plan is 44,801 shares of common stock.
+Added: During the quarter ended March 31, 2024, n o n e of our directors or officers (as defined in Rule 16a-1(f) under the Exchange Act) adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or a “non-Rule 10b5-1 trading arrangement” (as each term is defined in Item 408 of Regulation S-K).
Amended and Restated Certificate of Incorporation of the Registrant (incorporated herein by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No.
4 unchanged sentences
001-37581), filed with the SEC on June 24, 2020).
+Added: Second Amended and Restated Employment Agreement, effective as of February 1, 2024, by and between the Registrant and Joseph Monahan (incorporated herein by reference to Exhibit 10.15 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 27, 2024).
+Added: Separation Agreement, Waiver, and Release, dated as of February 4, 2024, by and between the Registrant and Douglas Manion (incorporated herein by reference to Exhibit 10.18 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 27, 2024).
+Added: Letter Agreement, dated as of January 31, 2024, by and between the Registrant and Neal Walker (incorporated herein by reference to Exhibit 10.22 to the Registrant’s Annual Report on Form 10-K (File No.
+Added: 001-37581), filed with the SEC on February 27, 2024).
Certification of Principal Executive Officer under Section 302 of the Sarbanes-Oxley Act.
11 unchanged sentences
Section 1350, and are not being filed for purposes of Section 18 of the Exchange Act and are not to be incorporated by reference into any filing of the registrant, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
+Added: Indicates management contract or compensatory plan.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
ACLARIS THERAPEUTICS, INC.
−Removed: November 6, 2023
−Removed: /s/ Douglas Manion
−Removed: Douglas Manion
−Removed: President and Chief Executive Officer
+Added: /s/ Neal Walker
+Added: Interim President and Chief Executive Officer
(On behalf of the Registrant)
−Removed: November 6, 2023
/s/ Kevin Balthaser
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.